Risk Factors for Cataract After Palladium-103 Ophthalmic Plaque Radiation Therapy

Journal Article · Fri Jul 01 00:00:00 EDT 2011 · International Journal of Radiation Oncology, Biology and Physics

DOI:https://doi.org/10.1016/j.ijrobp.2010.02.051· OSTI ID:21587573

Chin, Kimberly J ^[1]; Guopei, Yu ^[2]; Patel, Neil S ^[1]

---

1. New York Eye Cancer Center, New York, NY (United States)
2. New York Eye and Ear Infirmary, New York, NY (United States)

Purpose: To examine how tumor characteristics and dose affect cataract development after plaque radiation therapy. Methods and Materials: Three hundred and eighty-four patients were diagnosed with uveal melanoma and treated with palladium-103 ({sup 103}Pd) plaque radiation therapy. Of these, 282 (74%) inclusion met exclusion criteria for follow-up time, tumor location, and phakic status. Then patient-, ophthalmic-, and radiation-specific factors (patient age, diabetes, hypertension, tumor location, tumor dimensions, and lens dose) were examined (by a Cox proportional regression model) as predictors for the development of radiation-related cataract. Results: Radiation cataract developed in 76 (24%) of patients at a mean follow-up of 39.8 months (range, 1-192). Patients with anteriorly located tumors were noted to have a higher incidence of cataract at 43.0% (43 of 100 patients) vs. 18.1% (33 cataracts per 182 patients) for posteriorly located tumors (p <0.0001). However, multivariate Cox proportional modeling showed that increasing patient age at time of treatment (p for trend = 0.0003) and higher lens dose (p for trend = 0.001) were the best predictors (biomarkers) for radiation cataract. Conclusions: Although anterior tumor location, greater tumor height, and increased patient age (at treatment) were associated with significantly greater risk for radiation cataract, dose to lens was the most significant factor.

• OSTI ID: 21587573
• Journal Information: International Journal of Radiation Oncology, Biology and Physics, Vol. 80, Issue 3; Other Information: DOI: 10.1016/j.ijrobp.2010.02.051; PII: S0360-3016(10)00407-4; Copyright (c) 2011 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.; Country of input: International Atomic Energy Agency (IAEA); ISSN 0360-3016
• Country of Publication: United States
• Language: English

Related Subjects

62 RADIOLOGY AND NUCLEAR MEDICINE
BIOLOGICAL MARKERS
CATARACTS
HAZARDS
HYPERTENSION
MELANOMAS
MULTIVARIATE ANALYSIS
PALLADIUM 103
RADIATION DOSES
RADIOTHERAPY
BETA DECAY RADIOISOTOPES
CARCINOMAS
CARDIOVASCULAR DISEASES
DAYS LIVING RADIOISOTOPES
DISEASES
DOSES
ELECTRON CAPTURE RADIOISOTOPES
EPITHELIOMAS
EVEN-ODD NUCLEI
INTERMEDIATE MASS NUCLEI
ISOTOPES
MATHEMATICS
MEDICINE
NEOPLASMS
NUCLEAR MEDICINE
NUCLEI
PALLADIUM ISOTOPES
RADIOISOTOPES
RADIOLOGY
SENSE ORGANS DISEASES
STATISTICS
SYMPTOMS
THERAPY
VASCULAR DISEASES